Medtronic plc announced on February 25 2026 that it has begun the commercial launch in Europe of its MiniMed Go™ Smart MDI system, a first‑of‑its‑kind solution that combines the InPen™ smart insulin pen with the Simplera™ continuous glucose monitoring sensor into a single mobile app.
The MiniMed Go system delivers real‑time glucose data, a built‑in dose calculator, and actionable dose alerts, all designed to simplify diabetes management for patients who use multiple daily injections. The integration of the InPen’s Bluetooth dose‑tracking and the Simplera sensor’s finger‑prick‑free readings provides a seamless, data‑driven experience that has not been available to MDI users before.
The product is approved for patients aged seven and older, with a child‑friendly version for ages two to six that requires adult supervision, expanding Medtronic’s reach across a broad age spectrum.
Over 15 million people worldwide rely on MDI therapy, and the MiniMed Go launch addresses this large unmet need by bringing the advanced algorithms of automated insulin delivery systems to a population that has historically had fewer technological options.
The European launch is built around the Simplera sensor; compatibility with Abbott’s Instinct Go sensor is pending CE approval in Europe, while the U.S. version was cleared with the Instinct sensor on January 12 2026 and Simplera compatibility is under FDA review.
The new system complements Medtronic’s existing MiniMed 780G insulin pump and other delivery solutions, strengthening the company’s position in the connected insulin pen market and reinforcing its broader diabetes technology strategy.
Que Dallara, EVP and president of Medtronic Diabetes and CEO‑designate of MiniMed, said, "For too long, people using injections have carried the weight of diabetes management without access to the algorithms that make automated insulin delivery systems so powerful. MiniMed Go™ is designed to change that — bringing the smarts of an AID system to individuals who prefer an insulin pen. The system helps take the guesswork out of MDI therapy, delivering simplicity and confidence in every dose."
The launch marks a significant milestone for Medtronic, positioning the company to improve adherence and glycemic control for a large, underserved patient population and setting the stage for future growth in the diabetes technology market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.